C-JNNGIsomorphic Labs
AI drug discovery, machine learning, digital biology
discoverydiscoveringsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-JNNG
C-JNNGC-JNNGAI drug discovery, machine learning, digital biology
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Subscribe 🌎 Demis Hassabis is the co-founder and CEO of Google DeepMind and Isomorphic Labs. He believes AI will help cure every disease on Earth within a decade. The day after he closed the Google I/O keynote, his team invited me to Mountain View to interview him about the Future of AI at Google Deepmind. We get into Gemini for Science, his AlphaFold work he was awarded the Nobel Prize for, and how Google DeepMind aims to cure every disease within the next decade. Demis also discusses his answers on the AGI timeline, AI’s potential in curing cancer and Alzheimer's, and why he believes the future of AI is directly tied to scientific discovery. Connect with Demis & Google Deepmind: Website - https://deepmind.google/ X - https://x.com/demishassabis LinkedIn - https://www.linkedin.com/in/demishassabis/ Connect With Roberto: Instagram - https://www.instagram.com/rpn TikTok - https://www.tiktok.com/@rpn X - https://x.com/rpnickson YouTube - https://www.youtube.com/@rpn/ About New
Nobel laureate Demis Hassabis just raised $2.1B to build the future of medicine. Zero patients. Two weeks ago — May 12, 2026 — Sir Demis Hassabis closed a Series B at $2.1 billion for Isomorphic Labs, the AI drug-discovery company he spun out of Google DeepMind in 2021. Hassabis is the same Nobel laureate who, in October 2024, won the Nobel Prize in Chemistry for AlphaFold — the AI system that solved the 50-year grand-challenge problem of protein folding in 2020. The $2.1B round is the largest private AI-biotech raise in history, second only to Uber among recent US tech IPOs. What hasn't happened yet: Isomorphic has not given its drug to a single human being. So why did anyone hand a Nobel laureate $2.1 billion to make drugs that don't exist yet? Because this has happened before. In April 1976, two men met for a 3-hour beer at Churchill's bar in San Francisco. One was a UCSF biochemist named Herbert Boyer. The other was a 28-year-old who'd just been fired from his job at Kleiner &
Isomorphic Labs has just raised $2.1 billion in new funding. Demis Hassabis announced it today, framing the round as a turbocharge for the company's stated mission - to one day solve all disease. Isomorphic is the DeepMind spinout built on AlphaFold, the Nobel-winning protein structure model. The new round, led by Thrive Capital with Alphabet alongside, dwarfs the $600 million Isomorphic raised in 2025. The cash buys time. Hassabis has pushed the company's first human trials from late 2025 to the end of 2026, with oncology candidates leading the pipeline. Existing partnerships with Novartis and Eli Lilly could pay close to $3 billion in milestones, but only if the drugs work in patients. The next eighteen months will tell us whether AlphaFold's lab-bench wins translate to the clinic. It's the biggest single bet yet on AI-designed medicine. If it lands, the rest of pharma is in trouble. --- Daily AI Roundup - the AI news that actually matters, every weekday, plus the Top
Demis Hassabis, the mind behind DeepMind and AlphaFold, just pulled in $2.1 billion for Isomorphic Labs. But the real story isn't the check size. It's WHO wrote it. Thrive Capital led the round. Alphabet and GV doubled down. And for the first time, two sovereign wealth funds from different continents: MGX (Abu Dhabi) and Temasek (Singapore), backed the same AI pharma play simultaneously. That's not just investor confidence. That's a signal about where AI is actually going. Isomorphic Labs is building IsoDDE, an AI platform that doesn't search existing drug databases. It designs novel molecules from scratch. Small molecules. Antibodies. RNA therapeutics. The thesis: collapse the drug discovery timeline from decades to months. Design faster. Fail cheaper. In this breakdown: why Hassabis' track record makes this different from every other AI pharma pitch, why sovereign wealth is moving NOW, and what this deal signals for every industry waiting on AI to cross from code to chemist
Demis Hassabis won the Nobel Prize in Chemistry in 2024. Not for a drug. Not for a treatment. For an AI that learned the shape of every protein in the human body. [Pause.] Most people said: incredible scientific achievement. Hassabis said: that is step one. [Beat.] Here is the problem he is trying to solve. Developing a single drug today takes 10 years. It costs billions of dollars. And it fails 90% of the time before it ever reaches a patient. Of every 10 drugs that enter clinical trials — 10 years of work, billions of dollars, thousands of scientific careers — only one makes it through. [Hold.] His company, Isomorphic Labs, is building a system that runs that entire process on a computer. Identify the target. Design the compound. Predict how it behaves. Minimize the side effects. End to end. Before a single experiment is run. The first human clinical trial of a fully AI-designed drug is expected before the end of this year. [Pause.] His long-term vision is this: you describe a diseas
Demis Hassabis is the Co-Founder & CEO of Google DeepMind - working on AGI, responsible for AI breakthroughs such as AlphaGo, the first program to beat the world champion at the game of Go; and AlphaFold, which cracked the 50-year grand challenge of protein structure prediction and was recognised with the 2024 Nobel Prize in Chemistry. Demis is revolutionising drug discovery at Isomorphic Labs. Ultimately, trying to understand the fundamental nature of reality. ----------------------------------------------- Timestamps: 00:00 Intro 01:21 What Actually Counts as AGI & Where Are We Today? 02:58 What Are the Biggest Bottlenecks Holding AI Back Today? 03:48 Have We Hit the Limits of Scaling Laws? 04:40 Where Is AI Ahead of Expectations & What's Still Missing? 05:24 Why Can't AI Systems Learn Continuously Like Humans? 06:10 How Did DeepMind Go from Behind to Leading the Pack? 09:10 Are We Heading Toward Model Commoditization? 09:59 What Does the Future of Open Source Really Look Like? 11:
He solved “the most important unsolved problem in science”… If you need more optimistic science and tech stories, subscribe to support HUGE*! Demis Hassabis is a Nobel Prize winner and CEO of Google DeepMind. He is one of the most important people alive on what is quickly becoming the biggest technological advance of our lifetime. Because the biggest way AI is going to impact your life, you can’t see. It’s not a chatbot or an image generator. It’s the tools he and his team are building that are invisible to you – in new drug design, nuclear fusion, natural disasters detection, quantum computers. So who Demis is and what he chooses to build matters a lot. And he’s fascinating… He’s a childhood chess prodigy who at 17 turned down a reportedly million dollar job offer from a gaming company to go to college instead, and then get a PhD in neuroscience. He founded his company DeepMind with a mission to “solve intelligence” – starting with beating video games. He sold that company to
At India AI Summit 2026, Demis Hassabis, CEO of Google DeepMind and Isomorphic Labs, shared insights on the evolution of Artificial Intelligence. He reflected on the 2013 deep reinforcement learning breakthrough that mastered Atari games and discussed today’s advancements like Gemini Robotics. Hassabis highlighted the debate between general AI systems and specialized tools like AlphaFold, while predicting major breakthroughs in robotics within 2–3 years. He also emphasized AI’s transformative potential for India’s youth and the Global South through open-source innovation. Moneycontrol is India’s leading financial portal, offering market news, expert analysis, and powerful tools. A part of Network18, moneycontrol.com is India’s most trusted destination for financial and business news. #live #livenews #latestnews #topnews #moneycontrol #moneycontrollive #businessnews #businessnewslive #stockmarket #stockmarket #sharemarketnews #stockmarketliveupdates Subscribe: https://bit.ly/moneycon
Google DeepMind founder and CEO Sir Demis Hassabis is a master chess player, a recipient of the Nobel Prize in Chemistry, and - as of 2024 - a Knight. Today, as a leader within Google’s booming AI team, Hassabis wants to make AI the “engine” driving the entire company. In this episode of Fortune 500: Titans and Disruptors of Industry, Fortune’s Editor-in-Chief Alyson Shontell sits down with Hassabis at the World Economic Forum in Davos to talk about how he and his companies are using AI to cure cancer, build universal agents, and move the world towards a future of “radical abundance.” 00:00 Intro 01:25 Demis’ background 02:20 Founding DeepMind 03:15 Google’s DeepMind acquisition 05:25 Intro AlphaGo and AlphaFold 06:30 AlphaFold and the Protein Folding Problem 08:25 Isomorphic Labs and AI for Drug Discovery 10:45 General Drug Discovery Engine 11:30 Running Google DeepMind and Isomorphic 12:30 Hassabis’ work/sleep schedule 13:10 Google Merges Google DeepMind and Brain 17:25 Alphabet Sh
Key Points: - "Maybe we need one or two more breakthroughs..." - LLM are a Key Component or the Only Component - "Hybrid Systems" / "Neuro Symbolic Systems" can never be AGI. - Learning (+New Knowledge) is a critical part of AGI - Continual Learning - AlphaGo already proved that we can have AI do continual learning (from scratch). - A model that changes over time is ideal Sir Demis Hassabis is the CEO and co-founder of Google DeepMind and Isomorphic Labs, and a UK Government AI Adviser. From the interview with Alex Kantrowitz - "Google DeepMind CEO Demis Hassabis: AI's Next Breakthroughs, AGI Timeline, Google's AI Glasses Bet"
*Get our Resource Vault - a curated collection of pro-level business resources (tools, guides, databases)* https://clickhubspot.com/dba Episode 786: Sam Parr ( https://x.com/theSamParr ) and Shaan Puri ( https://x.com/ShaanVP ) tell the story Demis Hassabis ( https://x.com/demishassabis ) and the creation of Deepmind. Show Notes: (00:00) Demis the Menace (22:05) The only resource you need is resourcefulness (24:57) Move 37 (29:38) The olympics of protein folding (46:39) We are the gorillas — Links: • The Thinking Game - https://www.youtube.com/watch?v=d95J8yzvjbQ • Why We Do What We Do - https://www.youtube.com/watch?v=BwFOwyoH-3g • Fierce Nerds - https://paulgraham.com/fn.html • Isomorphic Labs - https://www.isomorphiclabs.com/ • If Anyone Builds It, Everyone Dies - https://ifanyonebuildsit.com/ — Check Out Sam's Stuff: • Hampton (joinhampton.com): My community for founders. Average member does $25m/year. Many of the guests are members. Get after it...apply: http://joi
“Este tipo quiere curar el cáncer”. Así describía un exejecutivo de Google DeepMind a Demis Hassabis: niño prodigio del ajedrez, diseñador de videojuegos, Nobel 2024, neurocientífico y, hoy, director de Google DeepMind. En este vídeo recorremos la vida de una de las figuras más influyentes de la inteligencia artificial moderna: desde sus primeras partidas de ajedrez y el videojuego Theme Park, hasta hitos como AlphaGo y AlphaFold, pasando por su visión ética sobre la IA y su obsesión por usarla para resolver los grandes problemas de la humanidad. 👉 Si te sirvió, suscríbete y mira la playlist “¿Quién es…en la IA?”. https://www.youtube.com/playlist?list=PLMuFdvXf84BKg0nV8KzPvi9-6E5C9bpWG Capítulos abajo 👇 y fuentes/créditos al final. ⏱ Capítulos 0:00 – Introducción: el hombre que quiere “curar el cáncer” 0:47 – De niño prodigio del ajedrez a los videojuegos (Theme Park) 3:03 – DeepMind: resolver la inteligencia para resolver el resto 5:43 – AlphaGo vs Lee Sedol: la partida que ca
Demis Hassabis says Isomorphic Labs is building on AlphaFold to transform drug discovery
Google DeepMind Co-Founder and Chief Executive Officer Demis Hassabis is positioning Google to win the artificial general intelligence, or AGI, race. He is also on a mission to harness AI to "solve all disease," including cancer, though his work at London-based Alphabet Inc. subsidiary, Isomorphic Labs. Launched by Alphabet in 2021, Isomorphic Labs is on a mission to radically accelerate drug development. Hassabis speaks exclusively to Bloomberg's Tom Mackenzie. Watch the full episode: https://youtu.be/3IZagDdwIno 00:00 - Can AI solve all disease? 00:40 - Can AI speed up drug discovery? 01:20 - Curing cancer with AI 02:28 - AI in drug trials 04:00 - AI talent wars 04:45 - Looking beyond AlphaFold 06:25 - Applying AI beyond medicine 08:02 - Can AI help us live longer? -------- Like this video? Subscribe to Bloomberg Technology on YouTube: https://www.youtube.com/channel/UCrM7B7SL_g1edFOnmj-SDKg Watch the latest full episodes of "Bloomberg Technology" with Caroline Hyde and Ed
AI-powered drug discovery: is it the next frontier of medicine? From cutting down costs, to speeding up development, the technology promises plenty - but can it deliver? In this episode, Bloomberg's Tom Mackenzie speaks exclusively to Demis Hassabis, the Nobel Laureate aiming to literally "solve all disease" through his work at London-based Isomorphic Labs. Hassabis' work comes in addition to his responsibilities at Alphabet Inc., where he oversees all of the company's core AI work as co-founder and CEO of Google DeepMind. --- "Bloomberg Tech: Europe" spotlights the biggest names and trends shaping the region's technology ecosystem as the global competition heats up. This monthly, 30-minute magazine-style show features in-depth interviews with top technology leaders, as well as major investors and policymakers - giving you a compelling A to Z of the most consequential innovations, opportunities and challenges. Chapters: 00:00:00 - Bloomberg Tech: Europe 00:01:16 - Isomorphic Labs
Panel discussion Moderator: Kinga Bercsenyi, Arctoris Panellists: Peter Brady, Orbital Global Group, Rose Hughes, Evolve IP, Anusha Foy, EY, Catherine Stace, Kuano Limited, Miles Congreve, Isomorphic Labs
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Lex Fridman Podcast full episode: https://www.youtube.com/watch?v=-HzgcbRXUK8 Thank you for listening ❤ Check out our sponsors: https://lexfridman.com/sponsors/cv9072-sb See below for guest bio, links, and to give feedback, submit questions, contact Lex, etc. *GUEST BIO:* Demis Hassabis is the CEO of Google DeepMind and Nobel Prize winner for his groundbreaking work in protein structure prediction using AI. *CONTACT LEX:* *Feedback* - give feedback to Lex: https://lexfridman.com/survey *AMA* - submit questions, videos or call-in: https://lexfridman.com/ama *Hiring* - join our team: https://lexfridman.com/hiring *Other* - other ways to get in touch: https://lexfridman.com/contact *EPISODE LINKS:* Demis's X: https://x.com/demishassabis DeepMind's X: https://x.com/GoogleDeepMind DeepMind's Instagram: https://instagram.com/GoogleDeepMind DeepMind's Website: https://deepmind.google/ Gemini's Website: https://gemini.google.com/ Isomorphic Labs: https://isomorphiclabs.com/ The MANIAC (book
Lex Fridman Podcast full episode: https://www.youtube.com/watch?v=-HzgcbRXUK8 Thank you for listening ❤ Check out our sponsors: https://lexfridman.com/sponsors/cv9092-sb See below for guest bio, links, and to give feedback, submit questions, contact Lex, etc. *GUEST BIO:* Demis Hassabis is the CEO of Google DeepMind and Nobel Prize winner for his groundbreaking work in protein structure prediction using AI. *CONTACT LEX:* *Feedback* - give feedback to Lex: https://lexfridman.com/survey *AMA* - submit questions, videos or call-in: https://lexfridman.com/ama *Hiring* - join our team: https://lexfridman.com/hiring *Other* - other ways to get in touch: https://lexfridman.com/contact *EPISODE LINKS:* Demis's X: https://x.com/demishassabis DeepMind's X: https://x.com/GoogleDeepMind DeepMind's Instagram: https://instagram.com/GoogleDeepMind DeepMind's Website: https://deepmind.google/ Gemini's Website: https://gemini.google.com/ Isomorphic Labs: https://isomorphiclabs.com/ The MANIAC (book
Lex Fridman Podcast full episode: https://www.youtube.com/watch?v=-HzgcbRXUK8 Thank you for listening ❤ Check out our sponsors: https://lexfridman.com/sponsors/cv9091-sb See below for guest bio, links, and to give feedback, submit questions, contact Lex, etc. *GUEST BIO:* Demis Hassabis is the CEO of Google DeepMind and Nobel Prize winner for his groundbreaking work in protein structure prediction using AI. *CONTACT LEX:* *Feedback* - give feedback to Lex: https://lexfridman.com/survey *AMA* - submit questions, videos or call-in: https://lexfridman.com/ama *Hiring* - join our team: https://lexfridman.com/hiring *Other* - other ways to get in touch: https://lexfridman.com/contact *EPISODE LINKS:* Demis's X: https://x.com/demishassabis DeepMind's X: https://x.com/GoogleDeepMind DeepMind's Instagram: https://instagram.com/GoogleDeepMind DeepMind's Website: https://deepmind.google/ Gemini's Website: https://gemini.google.com/ Isomorphic Labs: https://isomorphiclabs.com/ The MANIAC (book
Demis Hassabis is the CEO of Google DeepMind and Nobel Prize winner for his groundbreaking work in protein structure prediction using AI. Thank you for listening ❤ Check out our sponsors: https://lexfridman.com/sponsors/ep475-sb See below for timestamps, transcript, and to give feedback, submit questions, contact Lex, etc. *Transcript:* https://lexfridman.com/demis-hassabis-2-transcript *CONTACT LEX:* *Feedback* - give feedback to Lex: https://lexfridman.com/survey *AMA* - submit questions, videos or call-in: https://lexfridman.com/ama *Hiring* - join our team: https://lexfridman.com/hiring *Other* - other ways to get in touch: https://lexfridman.com/contact *EPISODE LINKS:* Demis's X: https://x.com/demishassabis DeepMind's X: https://x.com/GoogleDeepMind DeepMind's Instagram: https://instagram.com/GoogleDeepMind DeepMind's Website: https://deepmind.google/ Gemini's Website: https://gemini.google.com/ Isomorphic Labs: https://isomorphiclabs.com/ The MANIAC (book): https://amzn.to/4l
AI is changing the way we fight diseases. Founded by Nobel laureate Sir Demis Hassabis, Isomorphic Labs recently secured $600 million in funding to revolutionize medicine. Their AI models, including AlphaFold 3, predict 3D protein structures to help scientists design life-saving drugs faster and more efficiently. - Faster drug discovery - Lower development costs - Solving complex diseases The future of medicine is here. For more AI related updates, follow @trillionstech.ai
KEYNOTE Dr Miles Congreve - Chief Scientific Officer, Isomorphic Labs
Google DeepMind CEO and Co-Founder Demis Hassabis speaks with Bloomberg's Tom Mackenzie about the latest version of the company's AlphaFold AI system (AlphaFold 3), intended to tackle problems in biology including disease protection and treatment. Hassabis also discusses the hype cycle in AI, as well as the timeframe for AI-developed drugs and why he thinks Alphabet subsidiary Isomorphic Labs could be a $100 billion company. 00:00 - Intro 00:32 - AlphaFold 3, understanding dynamic picture of protein interactions 01:28 - Timeline for AI derived drugs. Partnerships with Eli Lilly and Novartis 02:03 - Isomorphic Labs, drug discovery 02:05 - Potential for mRNA vaccines 03:25 - Competitive threat from OpenAI 04:24 - Sustainability of AI 06:10 - Rationalization in AI sector, more closures and failures 07:14 - UK AI safety summit 08:47 - Big election year - are Labour as invested in AI? 09:20 - What are the big things coming this year? 10:31 - Isomorphic Labs, under pressure to commercialize
Demis Hassabis, CEO of Google DeepMind and Isomorphic Labs
Independent Sales Organization Login Online Banking Deposit Express Download Our App Contact Us Investor Relations Sign In --> Law Firm Solutions Back Law Firm Solutions Law Firm Banking Deposit Solutions Case Cost Financing Solutions Growth Capital Solutions Working Capital Solutions Plaintiff Solutions Capital that Goes the Distance Customer Success Stories Catastrophic Injury Law Firms High Case Volume Law Firms Class Action/Mass Tort Law Firms Qualified Settlement Funds Solutions Law Firm Tools & Resources Local Regional Advisor Law Firm Growth Team Ethics Opinion Social Justice Advocacy L
Sponsorships | California ISO Skip to main content California ISO Search Systems and applications Portals and applications Release planning Requesting access and certificates User Access Administrator (UAA) Library Recent documents Topics Meetings and events Calendar Events Meetings Daily Briefing Systems and applications Portals and applications Release planning Requesting access and certificates User Access Administrator (UAA) Library Recent documents Topics Meetings and events Calendar Events Meetings Daily Briefing Home (current) --> About About The California ISO manages the flow of elect
Making developing country voices count Skip to main content Powered by Capacity Building Home About Projects Digital learning Calendar Team Projects Making developing country voices count Supporting efficient participation of developing countries in international standardization contributes to a better integration in the global market. Almost three-quarters of ISO members are from developing countries, yet their participation in international standardization remains low. To ensure developing country interests are fairly represented and provided for, we help them participate more effectively in … ate actively in international committees. I presented an international standard proposal two years ago and now it is accepted for balloting. Beneficiary from Colombia Sectoral appoach - Pilot on Circular Economy The circular economy is of particular relevance to developing countries. For this reason, a sectoral capacity building journey is currently being piloted to ensure developing country interests are taken on board as early as possible in ISO’s standardization work … k on the circular economy by visiting the ISO/TC 323 page. Projects Apply good standardization practices Applying good standardization practices to help ISO members better serve the standardization needs of their countries. Adopt a strategic approach to standardization Identify and prioritize the needs of your country that can be addressed through standardization. Standards for effective public policy and regulation Enhancing the collaboration between standardizer
--> Security First Bank Announces New ATM ISO Sponsorship Program - Security First Bank Skip to content Welcome to Security First Bank --> Login Login --> Lenders / Agents Locations / ATMs Careers Contact Us Contact Us Proceed Finance Loan Servicing Login Personal Spend Personal Checking Accounts Personal Money Market Accounts Debit Cards Save Savings Accounts Time Deposits Health Savings Account HSA Individual Retirement Account (IRA) Borrow Personal Loans Auto Loans Home Mortgage Loans Personal Credit Cards Access Online Banking Mobile Banking Personal Finance Electronic Statements Bill Pay … ces Teller Express Courier Services Positive Pay Zelle® Small Business Mortgage Apply Mortgage Loan Options Mortgage Resources Mortgage Loan Servicing Insurance Get Insurance Quote Insurance Products Insurance Resources Financial Education About Us Lenders / Agents Locations / ATMs Careers Contact Us Contact Us Proceed Finance Loan Servicing Login Posted January 29, 2025 in Rapid City , Banking Updates Security First Bank Announces New ATM ISO Sponsorship Program Security Fir
ISO Sponsorship | Prosperity Bank FDIC-Insured – Backed by the full faith and credit of the U.S. Government Routing # 113122655 Accessibility Contact Us Locations & ATMs Search FDIC-Insured – Backed by the full faith and credit of the U.S. Government Routing # 113122655 Accessibility Contact Us Locations & ATMs Search Log In Personal Checking Accounts Compare Accounts Simply Free Checking eChecking Personal Checking Royal Checking Checking with Interest Interest Checking Plus Teen Checking Savings Accounts Compare Accounts Personal Money Market Personal Premier Money Market … s Aircraft and Boat Loans Mortgage Warehouse Lending Treasury Management Public Fund Services Merchant Services Lock Box Services Medical Professionals Physician Banking Medical Practice Loans and Lines Medical Investment Loans Medical Office Building Loans Mortgages Mortgages Real Estate Loans Construction Loans Home Equity Loans Prosperity Bank Home Loans Find A Loan Officer Borrower Guide Mortgage Inquiry Form Mortgage Calculators HOPP HOPP/ITIN Community Outreach Prosperi
ISO - Capacity building Google Consent Mode + Matomo TM --> Skip to main content Applications OBP English español français русский Menu Standards Sectors Health IT & related technologies Management & services Security, safety & risk Transport Energy Diversity & inclusion Environmental sustainability Food & agriculture Materials Building & construction Engineering About ISO Insights & news Insights All insights Healthcare Artificial intelligence Climate change Transport Cybersecurity Quality management Renewable energy Occupational health and safety Quantum computing News Expe
Isomorphic Labs announces $600m external investment round - Isomorphic Labs Our Team Our Tech Partnerships Careers Life At Iso Work With Us Job Openings News Our Team Our Tech Partnerships Careers Life at Iso Work with Us Job Openings News Announcement Isomorphic Labs announces $600m external investment round March 31, 2025 min Read min Read min Read min Read min listen min watch Copy url Table of Contents Listen: Spotify Apple Podcasts Isomorphic Labs announces it has raised $600 Million in its first external funding round. The financing round is led by Thrive Capital, with participation from … ng much-needed treatments to millions of patients globally. The company aims to apply its pioneering AI drug design engine to deliver biomedical breakthroughs and is advancing drug design programs across multiple therapeutic areas and drug modalities. Read more in the news release below. Isomorphic Labs announces $600 million funding to further develop its next-generation AI drug design engine and advance therapeutic programs into the clinic Read more Follow us Linkedin X Rel
Isomorphic Labs announces Series B investment round - Isomorphic Labs Our Team Our Tech Partnerships Careers Life At Iso Work With Us Job Openings News Our Team Our Tech Partnerships Careers Life at Iso Work with Us Job Openings News Announcement Isomorphic Labs announces Series B investment round May 12, 2026 min Read min Read min Read min Read min listen min watch Copy url Table of Contents Listen: Spotify Apple Podcasts Isomorphic Labs announces it has raised $2.1 Billion in Series B funding. The financing round is led by Thrive Capital, and includes participation from existing backers Alph … and GV alongside new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund, significantly expanding Isomorphic Labs’ global capital base. Isomorphic Labs was founded with the ambition to leverage the power of AI to reimagine and accelerate drug discovery to bring much-needed treatments to millions of patients globally. The company aims to apply its pioneering AI drug design engine (IsoDDE) to deliver biomedical breakthroughs and is advancing drug design programs acr
How to get a job at Isomorphic Labs - Isomorphic Labs Our Team Our Tech Partnerships Careers Life At Iso Work With Us Job Openings News Our Team Our Tech Partnerships Careers Life at Iso Work with Us Job Openings News Careers How to get a job at Isomorphic Labs July 18, 2023 min Read min Read min Read min Read min listen min watch Copy url Table of Contents Listen: Spotify Apple Podcasts People often ask me what it takes to get a job at Isomorphic Labs. Since our founding more than a year ago, we’ve been in high-growth mode, building our technology platform and recruiting many kinds of people, … mbers of the team. In my experience, sometimes talented individuals hesitate to apply for roles at companies like Isomorphic Labs, thinking they may not have all the skills and experiences necessary to land a role. Despite all of the impressive and accomplished people who work here, that’s a myth I have to dispel. While we all have to have the necessary skills to play our roles, we are purposefully seeking a diversity of backgrounds and don’t want to make cookie cutter hires. … racteristics we look for in the recruiting process, you need not be a genius to apply. Here’s what I look for, beyond technical skills, when I recruit for Iso: Experimental Mindset: We are actively looking for candidates to demonstrate a willingness to experiment - to push forward even when we’re not certain we’ll get the right outcome. In conversations, we often probe candidates to draw from their experience to show us that they are willing to explore, to try new things and
Work With Us - Isomorphic Labs Our Team Our Tech Partnerships Careers Life At Iso Work With Us Job Openings News Our Team Our Tech Partnerships Careers Life at Iso Work with Us Job Openings News Work With Us Creating an extraordinary company, together. We believe that to be successful we need a team with a range of skills and talents. We're building an environment where collaboration is fundamental, learning is shared and every team member feels supported and able to thrive. We value unique experiences, knowledge, backgrounds, and perspectives, and harness these qualities to create extrao … is based in Switzerland, you’ll need to have the right to work there before you apply. As for relocation support - absolutely. The talent acquisition team will tell you more about how we help new Isos and their families to make the move. recruitment process Does Iso use AI to assess job applicants? No, we believe in a human-centered approach to recruitment. Every application is reviewed by our team to ensure a fair and thoughtful evaluation process. When should I expect to he … ir and thoughtful evaluation process. When should I expect to hear back after I apply? We’re reviewing applications all the time, and will reply to everyone to let them know whether or not they have been invited for an initial call. We want to make sure we’re running a fair recruitment process. That means we sometimes leave roles open for extended periods of time to allow more people to apply. Can I apply for more than one open role at Iso? We find it’s better if you apply fo … see if you might be a better fit for a different position at Iso. Does Iso give application or interview feedback? If we interview you but it doesn’t go any further, we try our best to let you know within a few days. Because of the sheer number of applications we get every day, as much as we would like to, we will not be able to provide feedback to applicants who do not make it to the interview stage. Can I reapply if I was unsuccessful the first time around? We don’t recomme … r. We’ll also get in touch with you if we think there’s another role you should apply for instead. Tell us you’re interested in joining the team by completing the ‘General Application’ within our current job openings . Keep an eye on our social feeds on X and LinkedIn and our Work with us page – we’re a growing team, and new roles (technical and
Careers - Isomorphic Labs Our Team Our Tech Partnerships Careers Life At Iso Work With Us Job Openings News Our Team Our Tech Partnerships Careers Life at Iso Work with Us Job Openings News All news Careers Inside Isomorphic Labs' Lausanne office Modelling the invisible world of Molecular Biology with Machine Learning How to get a job at Isomorphic Labs Why I: Isomorphic Labs colleagues share what attracted them and inspires their work “It's both humbling and exciting to adopt a beginner’s mindset” - Having permission to be wrong Why I: Isomorphic Labs colleagues share why they joine
Careers - Isomorphic Labs Our Team Our Tech Partnerships Careers Life At Iso Work With Us Job Openings News Our Team Our Tech Partnerships Careers Life at Iso Work with Us Job Openings News All news Careers Inside Isomorphic Labs' Lausanne office Modelling the invisible world of Molecular Biology with Machine Learning How to get a job at Isomorphic Labs Why I: Isomorphic Labs colleagues share what attracted them and inspires their work “It's both humbling and exciting to adopt a beginner’s mindset” - Having permission to be wrong Why I: Isomorphic Labs colleagues share why they joine
Job Openings - Isomorphic Labs Our Team Our Tech Partnerships Careers Life At Iso Work With Us Job Openings News Our Team Our Tech Partnerships Careers Life at Iso Work with Us Job Openings News Current job openings Join our growing team of Isos What most people want to know working at iso Where is Iso based? Right now, we have one big Iso team operating in three great cities: London, UK (in the King’s Cross neighbourhood), Lausanne, Switzerland (in Le Flon district) and Cambridge, MA (in Kendall Square). We always tag the location of any open roles at Iso so you know where you’d be based. Doe … is based in Switzerland, you’ll need to have the right to work there before you apply. As for relocation support - absolutely. The talent acquisition team will tell you more about how we help new Isos and their families to make the move. recruitment process Does Iso use AI to assess job applicants? No, we believe in a human-centered approach to recruitment. Every application is reviewed by our team to ensure a fair and thoughtful evaluation process. When should I expect to he … ir and thoughtful evaluation process. When should I expect to hear back after I apply? We’re reviewing applications all the time, and will reply to everyone to let them know whether or not they have been invited for an initial call. We want to make sure we’re running a fair recruitment process. That means we sometimes leave roles open for extended periods of time to allow more people to apply. Can I apply for more than one open role at Iso? We find it’s better if you apply fo … see if you might be a better fit for a different position at Iso. Does Iso give application or interview feedback? If we interview you but it doesn’t go any further, we try our best to let you know within a few days. Because of the sheer number of applications we get every day, as much as we would like to, we will not be able to provide feedback to applicants who do not make it to the interview stage. Can I reapply if I was unsuccessful the first time around? We don’t recomme … r. We’ll also get in touch with you if we think there’s another role you should apply for instead. Tell us you’re interested in joining the team by completing the ‘General Application’ within our current job openings . Keep an eye on our social feeds on X and LinkedIn and our Work with us page – we’re a growing team, and new roles (technical and
Biotech behind AlphaFold hauls in $600M for next-gen AI model Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report Awards Gala Awards Outsourcing Awards Innovation Awards Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey … e’s GV and follow-on capital from Alphabet. Isomorphic will use the windfall to fund development of its next-generation artificial intelligence drug design model, the company announced in a March 31 release. The AI biotech is also looking to expand its team as it grows. "This funding will further turbocharge the development of our next-generation AI drug design engine, help us advance our own programs into clinical development, and is a significant step forward towards our mi … ssabis, along with DeepMind collaborator John Jumper, Ph.D., won the 2024 Nobel Prize in Chemistry for work on AlphaFold. In January 2024, Isomorphic inked two deals with Eli Lilly and Novartis worth up to nearly $3 billion combined. Both Big Pharma companies tasked Isomorphic with using AlphaFold to discover small molecules for undisclosed targets. In addition to these partnerships, Isomorphic is also working on wholly owned internal programs, according to the release. In Ma … tor interest in AI is still strong—especially if the company is backed by Nobel Prize-winning science. Isomorphic Labs Artificial Intelligence Google DeepMind AlphaFold GV (formerly Google Ventures) AI and Machine Learning Venture Capital Biotech Connect The Team Advertise Marketing Kit Let's Talk Join Us Newsletters Resources RSS Feeds Our Brands Fierce Pharma Fierce Biotech Fierce Healthcare Our Events Life Sciences Events ©2026 Questex LLC All rights reserved. Terms o
Isomorphic Labs' AI Generates Novel Drug Candidates | Anthony Rosenthal posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you … arch team’s words, generating. This matters beyond the immediate pharmaceutical application. The distinction between optimising within a known solution space and generating genuinely novel solutions is the conceptual border that AI sceptics have long argued language models cannot cross. The Isomorphic result is another data point from a narrow domain, suggesting that the border is not as firm as assumed. The question this raises for investors is not about drug discovery timel
Using our state-of-the-art AI models to power drug design - Isomorphic Labs Our Team Our Tech Partnerships Careers Life At Iso Work With Us Job Openings News Our Team Our Tech Partnerships Careers Life at Iso Work with Us Job Openings News Vision Using our state-of-the-art AI models to power drug design July 30, 2024 min Read min Read min Read min Read min listen min watch Copy url Table of Contents Listen: Spotify Apple Podcasts Pascal Savy joined Isomorphic Labs in December 2022 as a Research Leader in the Drug Design and Medical Research (DDMR) Team. Before joining Isomorphic Labs I was a
Isomorphic Labs secures $2.1 Billion funding to scale its AI drug design engine Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos M … and GV alongside new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund, significantly expanding Isomorphic Labs' global capital base. The new capital will be used for the continued development and deployment of Isomorphic Labs' AI drug design engine (IsoDDE), accelerating and expanding its pipeline of therapeutic programs towards the clinic. Additionally, the funding will support our existing hiring targets by integrating world-class AI, engineering, drug design … hroughs with a level of precision and speed previously thought impossible. "The application of AI in healthcare offers a profound opportunity. Isomorphic Labs has already made extraordinary progress in harnessing AI to accelerate drug discovery, and we are excited by this momentum and the early promise of the technology platform," said Ruth Porat, President and Chief Investment Officer Alphabet and Google. "This trajectory is encouraging, and this funding will be used to acce … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
A Quest for a Cure: AI Drug De…–Google DeepMind: The Podcast – Apple Podcasts Search Home New Top Charts Search 5 June 2025 45 min A Quest for a Cure: AI Drug Design with Isomorphic Labs Google DeepMind: The Podcast Play In this episode, host Hannah Fry is joined by Max Jaderberg and Rebecca Paul of Isomorphic Labs to explore the future of drug discovery in the age of AI. They discuss how new technology, particularly AlphaFold 3, is revolutionizing the field by predicting the structure of life’s molecules, paving the way for faster and more efficient drug discovery. They dig into the immense c
Speaker Spotlight: Demis Hassabis - Co-Founder & CEO of DeepMind Skip to content [email protected] 0203 4109897 Twitter Linkedin Youtube Search for: About Speakers All AI Speakers Agentic AI Cryptocurrency Cyber Security Data & Privacy Data Sovereignty Environment & Sustainability Ethical AI Finance & Fintech Future of Work Generative AI & ChatGPT Government & Public Policy Machine Learning Quantum Robotics Startups & Innovation The Process News Contact Us P E Menu About Speakers All AI Speakers Agentic AI Cryptocurrency Cyber Security Data & P … omputational models of learning. Demis later held a Henry Wellcome postdoctoral fellowship at UCL’s Gatsby Computational Neuroscience Unit and worked as a visiting scientist at MIT and Harvard University. In 2010, he co-founded DeepMind with Shane Legg and Mustafa Suleyman. The company’s mission—to understand intelligence and use it to advance society—has led to some of the most significant breakthroughs in AI, including AlphaGo, the first program to defeat Go world champion … res and revolutionises biomedical science. In 2024, Demis was awarded the Nobel Prize in Chemistry for his work on AlphaFold – see him speak at The Nobel Prize ceremony, below. Now owned by Google, DeepMind has also partnered with the NHS and Moorfields Eye Hospital to improve medical diagnostics. In 2021, Demis founded Isomorphic Labs to apply AI to drug discovery. As a keynote speaker, he shares insights on innovation, ethics, and the future of intelligence, inspiring … Most Influential People, STAT Status List & Ukie Hall of Fame 2024 – Nobel Prize in Chemistry, Clarivate Citation Laureate, Keio Medical Science Prize, The AI Citizen of the Year, Included in the Time 100 AI list, Science Museum Group Fellowship Award, Honorary degree from the University of Oxford & Knight Bachelor for services to artificial intelligence 2023 – BCS Lovelace Medal, UCL Prize Lecture in Life and Medical Sciences, Albert Lasker Award for Basic Medical R … ime 100 AI list, Member of the Academia Europaea, Canada Gairdner International Award, Ordinary Member of the Pontifical Academy of Sciences & Breakthrough Prize in Life Sciences for developing AlphaFold 2022 – VinFuture Prize for Innovators with Outstanding Achievements in Emerging Fields, Global Swiss AI Award, BBVA Foundation Frontiers of
Instagram Instagram Log In Sign Up Close Never miss a post from biotechtvhq Sign up for Instagram to stay in the loop. Sign up Log in biotechtvhq Verified • Follow Original audio More options biotechtvhq Verified 60w 𝐀𝐈 𝐍𝐞𝐰𝐬: Despite the biotech sector’s headwinds, some companies are still attracting investors. Google spinout Isomorphic Labs recently announced a $600 million funding round, the industry’s largest this year. Check out this video to learn how they’re using AI. Load more comments No comments yet. Start the conversation. Like 5 Comment Share Save April 5, 2025 Log in to like
Isomorphic Labs builds U.S. presence, with an eye on clinical trials Skip to Main Content Manage alerts for this article Email this article Share this article Cancer ASCO FDA Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT@ASCO Search Log In Try STAT+ My Account Home News Latest STAT10 Business Biotech Pharma He … ificial intelligence , Clinical trials , drug development , health tech , STAT+ Submit a correction request Reprints Katie Palmer Health Tech Correspondent Katie covers the impact of health technology on patients, clinicians, and businesses. Her stories explore the price tag of clinical AI, digital health at the FDA, and the boom in direct-to-consumer telehealth. Confidential tips can be sent on Signal at palmer.01. STAT+ Newsletter A hitchhiker's guide to the health car
Isomorphic Labs prepares to launch trials for AI-designed drugs Skip to site menu Skip to page content Switch language: .translate --> CT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Approvals Operations Outsourced Services Supply Chain Data Management Medical Devices Themes Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filings Patents Social Media Companies Company A-Z Company Categories Product & Se … AlphaFold 3 system, developed with Google DeepMind, won its developers a Nobel Prize. Image credit: Shutterstock / Robert Way Alphabet’s AI drug development subsidiary Isomorphic Labs is aiming to initiate clinical trials for its AI-developed oncology drugs. In an interview with Fortune , Isomorphic Labs president Colin Murdoch shared that four years after its founding, the company is preparing to dose the first patients in clinical trials. He added that the business i … s. AlphaFold was developed by John Jumper and Demis Hassabis, who won the Nobel Prize in 2024. Isomorphic Labs has been working on other AI models to help design new therapies. In March 2025, Isomorphic Labs raised $600m via a financing round led by Thrive Capital, which has been used to continue developing the AI drug-design engine and advance the pipeline into clinical trials. “This funding will further turbocharge the development of our next-generation AI drug design engin
Isomorphic Labs Raises $2.1B for AI-Powered Drug Design | Aditya ⚡️ Rao posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agr
Instagram Instagram Log In Sign Up Close Never miss a post from theneurondaily Sign up for Instagram to stay in the loop. Sign up Log in theneurondaily • Follow Original audio More options theneurondaily 2w For decades, scientists called K-RAS “undruggable.” 🧬💊 Now researchers are finally seeing breakthroughs. Isomorphic Labs explains how AI could help unlock treatments for diseases and biological targets that were once considered impossible to treat. Watch the full episode now. Link in bio. #AI #Biotech #DrugDiscovery #Healthcare #CancerResearch #Tech Load more comments No comments yet. Sta
PKPD Modelling Lead, London – Isomorphic Labs – Job London, England Talent.com Search jobs Search salary Tax calculator For employers Sign in Find jobs PKPD Modelling Lead, London Isomorphic Labs • City Of London, England, GB Apply No longer accepting applications PKPD Modelling Lead, London Isomorphic Labs • City Of London, England, GB 30+ days ago Job type Full-time Job description About Iso Isomorphic Labs (IsoLabs) was launched in 2021 to advance human health by building on and beyond the Nobel-winning AlphaFold system. Since then, our interdisciplinary team of drug discovery experts and m … ese if you’re selected for an initial screening call. Please note that when you submit an application, your data will be processed in line with our privacy policy. #J-18808-Ljbffr Create a job alert for this search PKPD Modelling Lead, London • City Of London, England, GB Create Similar jobs Senior Analyst, Model Development Team - London (6 Month FTC) Fitch Ratings • Greater London, England, United Kingdom Permanent +1 As one of the world’s top three credit ratings agencies, … Of London, England, United Kingdom Temporary Hybrid (2 days per week in office).Apply online only) GBP/day on Inside IR35 on Umbrella.We are seeking an ML Lead to manage our team and spearhead the design and deployment of cutting‑edge Agentic... Show more Last updated: 28 days ago • Promoted Global Measurement Practice Lead TAL Life LTD • Greater London, England, United Kingdom Full-time Global Measurement Practice Lead.MiQ is a programmatic media partner focusing on data sci
Isomorphic Labs, a subsidiary of Alphabet, announced the start of the first phase of clinical trials for its drug. The innovative approach to drug development is entirely based on artificial… | Denys L. LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in … sights into the crucial aspects of protein-ligand interactions and learn how to apply docking techniques to predict the behavior of drug molecules. This course is essential for anyone looking to understand the molecular interactions that underpin drug efficacy. ✅DD12003 - Machine Learning and Representation Learning for Drug Discovery Discover how machine learning and representation learning are revolutionizing drug discovery. This course focuses on the application of these a
Isomorphic Labs lands $2.1 billion to expand AI-driven drug discovery | The Pharmaletter Wednesday 3 June 2026 About Contact Login VC & Investment M&A AI Podcasts News Pharmaceutical News Biotechnology News Generics News Biosimilars news In Brief Legal Company Pages In The Boardroom Insights Analysis Special Report Interviews Expert View From Our Correspondent One To Watch Companies Digital Pharma Pharma Leaders Regulatory FDA EMA Pricing, Reimbursement and Access Regulation Government Affairs Trump Administration Therapy Areas Dermatologicals Oncology Neurological Rare Diseases Hemato
Instagram Instagram Log In Sign Up Close Never miss a post from startupsceneme Sign up for Instagram to stay in the loop. Sign up Log in Tags scenenowuae startupsceneme and scenenowuae More options startupsceneme Edited • 2w @StartupSceneME : Isomorphic Labs, a London-based biotechnology company that uses artificial intelligence to accelerate drug discovery and therapeutic development, has raised $2.1 billion in a Series B funding round led by Thrive Capital, with participation from Abu Dhabi-based investment firm MGX. The investment syndicate also included Alphabet, GV, Temasek, CapitalG, and … yndicate also included Alphabet, GV, Temasek, CapitalG, and the UK Sovereign AI Fund. Founded in 2021 by Demis Hassabis, the company describes itself as an AI-first drug design and development firm focused on accelerating pharmaceutical discovery across multiple therapeutic areas. According to the company, the new capital will be used to expand its AI drug design engine, IsoDDE, alongside recruitment across artificial intelligence, engineering, drug design, and clinical resea
Isomorphic Labs announces $600 million funding | The Pharmaletter Wednesday 3 June 2026 About Contact Login VC & Investment M&A AI Podcasts News Pharmaceutical News Biotechnology News Generics News Biosimilars news In Brief Legal Company Pages In The Boardroom Insights Analysis Special Report Interviews Expert View From Our Correspondent One To Watch Companies Digital Pharma Pharma Leaders Regulatory FDA EMA Pricing, Reimbursement and Access Regulation Government Affairs Trump Administration Therapy Areas Dermatologicals Oncology Neurological Rare Diseases Hematology Cardio Vascular Di
One moment, please... Loader Please wait while your request is being verified...
#jpmhc26 | Isomorphic Labs LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Cookie Policy . Skip
Isomorphic Labs - BIO International Convention 2026 Start your engines! BIO 2026 is June 22-25 at the San Diego Convention Center. Program announced! See the 130+ sessions in 18 focus areas. Generate Your Personal Event Schedule in Seconds! GENERATE NOW Start your engines! BIO 2026 is June 22-25 at the San Diego Convention Center. Program announced! See the 130+ sessions in 18 focus areas. Generate Your Personal Event Schedule in Seconds! GENERATE NOW June 22-25 | San Diego Event Info Event Overview About BIO International Convention Future dates Attendee Policies Schedule at a Glance F … ific Progress AI Implementation Biomanufacturing Academia Company Presentations Apply for a Company Presentation 2026 Presenting Companies Curated Programs AI Summit BIO Storytelling Stage BioProcess Theater Global Innovation Hubs Professional Development Courses Start-Up Stadium Student Program BIO Partnering™ BIO Partnering™ at BIO 2026 BIO Partnering™ Overview Pre-Event Webinars Partnering Resources LOG IN TO BIO PARTNERING Participating Companies All Companies Participati … g™ Spotlights Amgen Genentech Boehringer Ingelheim Lilly Sanofi Academic Campus Apply for Academic Campus Exhibition Exhibition Directory Exhibitor List Exhibition Map Networking Networking at BIO Receptions Exhibitor In-Booth Events Other Events Social Spotlight Events Affiliate Events Application List your event Special Experiences 5K and 1 Mile Course Match Day Lounge Travel Hotel Reservations Book Your Hotel Interactive Hotel Map Hotels by Amenity Hotel Guidelines Transpo
Demis Hassabis' Isomorphic Labs Reimagines Drug Discovery with $2.1b Funding | Ipek Celiksoz posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to … round, joined by JME Ventures , Big Sur Ventures , Masia , and a new UK stealth fund. 🫶 Welcome to the Norrsken Evolve portfolio, Alex Ward , Caelan Anderson , and the rest of the Tolemy Bio team! 147 4 Comments Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Universal Biotechnology -The Path Of Research 1,627 followers 2w Report this post 🚨𝗕𝗜𝗚𝗚𝗘𝗦𝗧 𝗕𝗜𝗢𝗧𝗘𝗖𝗛 𝗕𝗥𝗘𝗔𝗞𝗧𝗛𝗥𝗢𝗨𝗚𝗛 𝗧𝗛𝗜𝗦 𝗪𝗘𝗘𝗞🧬🤖 The biotech world is evolvin … ield. Backed by Thrive Capital, Alphabet, Temasek, MGX, and the UK Sovereign AI Fund, this is no longer just a venture story. Governments are treating AI-driven medicine as strategic infrastructure. Building on Nobel Prize-winning AlphaFold, Isomorphic is pushing towards something even more ambitious, an AI engine that doesn't just predict biology, but designs medicines from first principles. This raises some big questions for our industry: 💰 For investors: how are you weigh
Isomorphic Labs is using Google Cloud’s AI Hypercomputer to reimagine drug discovery - YouTube Tietoja Lehdistö Tekijänoikeudet Ota yhteyttä Sisällöntuottajat Mainosta Kehittäjät Ehdot Tietosuoja Käytännöt ja turvallisuus Näin YouTube toimii Kokeile uusia ominaisuuksia © 2026 Google LLC
A quest for a cure: AI drug design with Isomorphic Labs - Isomorphic Labs Our Team Our Tech Partnerships Careers Life At Iso Work With Us Job Openings News Our Team Our Tech Partnerships Careers Life at Iso Work with Us Job Openings News Video A quest for a cure: AI drug design with Isomorphic Labs June 5, 2025 min Read min Read min Read min Read 47 min listen 47 min watch Copy url Table of Contents Listen: Spotify Apple Podcasts In this episode, host Hannah Fry is joined by our Head of Medicinal Chemistry, Rebecca Paul and our Chief AI Officer, Max Jaderberg, to explore the future of drug dis
Our Tech - Isomorphic Labs Our Team Our Tech Partnerships Careers Life At Iso Work With Us Job Openings News Our Team Our Tech Partnerships Careers Life at Iso Work with Us Job Openings News Our Tech A unified drug design engine for a new era of discovery Redefining drug discovery The AI technology we have developed allow our researchers to explore a new chemical landscape. We can now take on historically challenging targets with extraordinary pace and accuracy. A heritage of breakthroughs Isomorphic Labs was launched from DeepMind, and many of our team contributed to the creation of the gro … e way medicine will help and heal people. “I believe there is no more important application for AI than helping to improve human health.” “I believe there is no more important application for AI than helping to improve human health.” SIR DEMIS HASSABIS FOUNDER AND CEO Isomorphic Labs’ unified drug design engine Where others may build solutions around a specific design target, Iso’s drug design engine is built on AI models capable of working across multiple therapeutic areas a
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Yahoo on osa Yahoo-konserni Sivustot ja sovellukset, jotka omistamme ja joita operoimme, mukaan lukien Yahoo ja Engadget, sekä digitaalinen mainospalvelumme (Yahoo Advertising). Yahoo-konsernia . Kun käytät sivustojamme ja sovelluksiamme, käytämme evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä tarjotaksemme sivustomme ja sovelluksemme sinul
Isomorphic Labs Discusses AI-D… - NVIDIA AI Podcast - Apple Podcasts Search Home New Top Charts Search April 16, 2025 39 min Isomorphic Labs Discusses AI-Driven Drug Discovery and the Future of Medicine NVIDIA AI Podcast Play Max Jaderberg and Sergei Yakneen from Isomorphic Labs discuss how AI is enhancing drug discovery by treating biology as an information processing system. They share how advanced AI models like AlphaFold 3 are accelerating the pipeline and paving the way for a future of precision medicine. Episode Webpage Information Show NVIDIA AI Podcast Frequency Updated Weekly Publishe
Isomorphic Labs’ Quest to ‘Solve All Diseases’ | Sequoia Capital Skip to main content Our Founders Our Companies Our Team Stories Podcasts Arc Open search The Quest to ‘Solve All Diseases’ with AI: Isomorphic Labs’ Max Jaderberg Episode 40 | Visit Training Data Series Page Jump to Key questions in RL Multiplayer games Finding the right recipe Working with Demis If everything goes right “A holy grail model” The breakthroughs of AlphaFold What kinds of data are missing? Limiting factors in drug development How do drug designers use AlphaFold 3? Building an interdisciplinary team AlphaFold Server … nciples thinking about entrenched challenges. Bridge the gap between theory and application: As AI accelerates drug design, the industry must reimagine how these molecules move through clinical trials. This means developing new ways to engage with regulatory bodies and incorporate AI predictions about molecular behavior and toxicity. The goal is to get therapeutics to patients faster while maintaining safety standards through better predictive understanding. Transcript Chapte … w do we create a very general drug design engine with AI, something that we can apply to not just a single target or even a single modality, where we can apply this again and again across any different disease area. And that’s what we’re stepping towards at the moment. Stephanie Zhan: Today we are excited to welcome Max Jaderberg to the show, Chief AI Officer of Isomorphic Labs, which launched out of DeepMind with a goal of revolutionizing drug discovery using AI. Last summer … heir interactions with each other. That led to Demis Hassabis winning the Nobel Prize in Chemistry last year. Max describes their vision for what a holy grail model for drug design and agents for science look like. He draws parallels to his experiences building AlphaStar and Capture The Flag, and the research directions of building agents in games more broadly. Specifically, with 10 to the power of 60 possible drug molecule structures, we need to build both generative models … e timing, too, with the launch of AlphaFold 3, and with Demis winning the Nobel Prize in chemistry, which is a true testament to everything that you and your team have done over the last couple years. Max Jaderberg: Yeah, 2024 was definitely a busy year for us. Lots of big breakthroughs. Nobel Prize was just incredible to see. You know, I think a
Accelerating drug discovery wi… - Gradient Dissent: Conversations on AI - Apple Podcasts Search Home New Top Charts Search April 25, 2024 1hr 10min Accelerating drug discovery with AI: Insights from Isomorphic Labs Gradient Dissent: Conversations on AI Play In this episode of Gradient Dissent, Isomorphic Labs Chief AI Officer Max Jaderberg, and Chief Technology Officer Sergei Yakneen join our host Lukas Biewald to discuss the advancements in biotech and drug discovery being unlocked with machine learning. With backgrounds in advanced AI research at DeepMind, Max and Sergei offer their unique i
Isomorphic Labs Rethinks Drug Discovery With AI | NVIDIA Blog Skip to content Isomorphic Labs Rethinks Drug Discovery With AI April 16, 2025 by Noah Kravitz 0 Comments Share Share This Article X Facebook LinkedIn Copy link Link copied! Isomorphic Labs is reimagining the drug discovery process with an AI-first approach. At the heart of this work is a new way of thinking about biology. Max Jaderberg, chief AI officer, and Sergei Yakneen, chief technology officer at Isomorphic Labs joined the AI Podcast to explain why they look at biology as an information processing system. “We’re building gener
Podcasts - Isomorphic Labs Our Team Our Tech Partnerships Careers Life At Iso Work With Us Job Openings News Our Team Our Tech Partnerships Careers Life at Iso Work with Us Job Openings News All news Podcasts The Quest to ‘Solve All Disease’ with AI: Isomorphic Labs’ Max Jaderberg A breakthrough unfolds. Google DeepMind: The Podcast featuring Demis Hassabis © 2026 ISOMORPHIC LABS Home Life at Iso Our Team Work With Us Our Tech Job Openings Partnerships News CONTACT US [email protected] [email protected] [email protected] INFO Privacy Notice Cookie Notice Terms &a
A breakthrough unfolds. Google DeepMind: The Podcast featuring Demis Hassabis - Isomorphic Labs Our Team Our Tech Partnerships Careers Life At Iso Work With Us Job Openings News Our Team Our Tech Partnerships Careers Life at Iso Work with Us Job Openings News Podcast A breakthrough unfolds. Google DeepMind: The Podcast featuring Demis Hassabis January 25, 2022 min Read min Read min Read min Read 40 min listen 40 min watch Copy url Sir Demis Hassabis, PhD Founder and CEO Table of Contents Listen: Spotify Apple Podcasts In this episode of Google DeepMind: The Podcast, Hannah Fry uncovers the ins … dicted”. This breakthrough AI model inspired the founding of Isomorphic Labs to apply cutting-edge AI to reimagine the entire drug discovery process. Related © 2026 ISOMORPHIC LABS Home Life at Iso Our Team Work With Us Our Tech Job Openings Partnerships News CONTACT US [email protected] [email protected] [email protected] INFO Privacy Notice Cookie Notice Terms & Conditions Supplier Code of Conduct Manage Cookies
How AlphaFold 3 is Changing Drug Discovery - BioTechniques Skip to main content BioTechniques is part of Taylor & Francis Group. Taylor & Francis About us Our journals Our Digital Hubs Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK. Taylor & Francis Home Journal Aims and scope Current Volume Editorial board For authors Your editors: what do we do? Follow us on social media News Latest news Tech news Events ne
Isomorphic raises $1.2bn for AI drug hunt | pharmaphorum Skip to main content Tuesday 2 June 2026 BlueSky linkedin youtube header links Get Newsletters Media Kit Pharmaphorum menu first category News Views & Analysis Deep Dive Equity and Sustainability Research & Development Market Access Oncology Artificial Intelligence Patients & Partnerships GLP-1 Previous Editions Webinars Podcasts Videos Spotlight on ASCO BIO-Europe C-Suite Innovators ESMO Frontiers Health JP Morgan Global Policy Insights Events close SECTION News Views & Analysis Deep Dive Research & Development Marke … nkedin BlueSky Sign in Isomorphic raises $1.2bn for AI drug hunt News The Nobel Prize via YouTube Isomorphic Labs' chief executive, Sir Demis Hassabis, delivering his Nobel Prize lecture in 2024. Alphabet-backed start-up Isomorphic Labs has added to the lustre attached to its AI-powered drug discovery engine by raising an eye-watering $1.2 billion in a Series B led by US venture firm Thrive Capital. The London, UK start-up said the massive round – also supported by Alpha … and GV, alongside new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund – will be used to refine its IsoDDE discovery platform, fund international expansion, and progress its drug candidate pipeline. It comes just over a year after Isomorphic, which is led by Google DeepMind founder Sir Demis Hassabis, raised $600 million in a first-round financing led by Thrive Capital and GV. The sheer scale of the Series B is another endorsement of Isomorphic, coming on top of … behind AlphaFold has received significant recognition, including the 2024 Nobel Prize in Chemistry, which went to Hassabis, John Jumper, and David Baker. Isomorphic Labs recently published (PDF) a subset of the capabilities of IsoDDE, highlighting its predictive accuracy and introducing new capabilities that bridge the gap between structure prediction and real-world drug discovery. In a statement, Isomorphic said the new financing will be used to move its drugs into clinical … ic said the new financing will be used to move its drugs into clinical testing, fund additional hirings of experts in AI, engineering, drug design, and clinical development across its sites in London, Lausanne in Switzerland, and Cambridge in Massachusetts, US. "This funding round is a massive vote of confidence from a diverse group of top-tier i
Demis Hassabis - Biography Flash - Podcast - Apple Podcasts Search Home New Top Charts Search Demis Hassabis - Biography Flash Inception Point AI 0.0 (0) Technology Explore the extraordinary life and ongoing impact of Sir Demis Hassabis in this in-depth biography podcast hosted by Vanessa Clark on the Biography Flash network. From child chess prodigy in London to teenage video game programmer behind the multi-million-selling Theme Park, from a Cambridge Double First in Computer Science to groundbreaking neuroscience research on imagination and memory at University College London, Demis Hassabi … y, medicine, and drug discovery, and ultimately earning Hassabis the 2024 Nobel Prize in Chemistry. The show covers his knighthood, his role as a UK Government AI Adviser, his leadership of Google DeepMind and its team of over two thousand researchers, and his founding of Isomorphic Labs to accelerate AI-driven drug discovery. Beyond the comprehensive biography, this podcast delivers regular updates on the latest news, breakthroughs, and developments surrounding Hassabis and … icles the extraordinary life of Sir Demis Hassabis, from chess prodigy to Nobel Prize-winning AI pioneer who co-founded DeepMind. Explore his groundbreaking work on AlphaGo, AlphaFold, and Google DeepMind's latest developments. Perfect for anyone fascinated by AI innovation and visionaries driving humanity forward. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch jus … rtificial intelligence with AlphaGo and AlphaFold, ultimately winning the Nobel Prize in Chemistry for solving protein structure prediction. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the h … icles the extraordinary life of Sir Demis Hassabis, from chess prodigy to Nobel Prize-winning AI pioneer who co-founded DeepMind. Explore his groundbreaking work on AlphaGo, AlphaFold, and Google DeepMind's latest developments. Perfect for anyone fascinated by AI innovation and visionaries driving humanity forward. Loved this episode? Discover mo
Sir Demis Hassabis’s Isomorphic Labs raises £1.6bn Business Cloud logo Choose Category Founder 250 list: Apply here Founders Naked Founder podcast Founder Friday Founder features Founder news News Insights Rankings/lists Northern Leaders 2025 Tech 50 innovation rankings Nominate for Tech 50s Events Newsletter Advertise About us Posted on May 12, 2026 by Jonathan Symcox Sir Demis Hassabis’s Isomorphic Labs raises £1.6bn DeepMind founder to use funding to power AI drug design engine, scale business globally and progress drug candidate pipeline Share: MedTech Investment Isomorphic Labs, an AI-fir … and GV alongside new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund, significantly expanding Isomorphic Labs’ global capital base. The new capital will be used for the continued development and deployment of Isomorphic Labs’ AI drug design engine (IsoDDE), accelerating and expanding its pipeline of therapeutic programs towards the clinic. Additionally, the funding will support its existing hiring targets by integrating AI, engineering, drug design … president and chief investment officer at Alphabet and Google, said: “The application of AI in healthcare offers a profound opportunity. “Isomorphic Labs has already made extraordinary progress in harnessing AI to accelerate drug discovery, and we are excited by this momentum and the early promise of the technology platform. “This trajectory is encouraging, and this funding will be used to accelerate the work and bring important interventions to market with greate … te is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Δ Already subscribed? News Insights Newsletter Events Contact us About us TechBlast Fire Up Co-Working Space, Old Fire Station Yard, Maclure Road, Rochdale OL11 1DN 0161 531 6630 [email protected] Content Appointments Deals Investment Sectors Cryptocurrency Cybersecurity EdTech EnviroTech FinTech HealthTech InsurTech LegalTech Manufacturing MarTech MediaTech MedTech PropTech Rec
Alphabet's AI biotech Isomorphic Labs bags $2.1B series B Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report Awards Gala Awards Outsourcing Awards Innovation Awards Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey … ’s GV. New backers included MGX, Temasek, CapitalG and the U.K. government’s AI fund. Isomorphic designs potential drugs with AI models such as AlphaFold 3 , a Google DeepMind-partnered model that can predict the structures and interactions of molecules. The new money will be used to develop and deploy Isomorphic’s AI drug design engine, dubbed IsoDDE, as well as accelerate its in-house drug pipeline into the clinic. Related Lilly pens $2.2B pact with Bezos-backed Profluent t
Isomorphic Labs Announces First Phase of Management Team - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Isomorphic Labs Announces First Phase of Management Team May 12, 2022 | 6 min read Twitter LinkedIn Facebook Email Print Isomorphic Labs, a subsidiary of Alphabet, today announced the first phase of its management team. May 12, 2022 12:00 UTC New additions include Chief Scientific Offi … expensive and high-risk process that is poised to benefit from advances in the application of AI and computational methods. Studies peg the cost of bringing a molecule to market at more than $2.5 billion per drug and timelines approaching a decade; in fact, only about 12 percent of drugs entering clinical trials are ultimately approved by the U.S. Food and Drug Administration (FDA). “We’re thrilled to announce the formation of our extraordinary multidisciplinary leadership t … and patents. In 2015, he was co-recipient of the RSC Malcolm Campbell Memorial Prize for the seminal contributions to GPCR drug discovery made by Sosei Heptares. Dr. Congreve has a degree in biological chemistry from Leicester University and a PhD in synthetic chemistry from Cambridge University. He is also a fellow of the Royal Society of Chemistry. SERGEI YAKNEEN, PhD Dr. Yakneen joins as Chief Technology Officer, bringing over 20 years of experience in engineering, machin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Agenda: AI in biopharma: Where promise meets pressure Toggle navigation Agenda Agenda Choose your pass AI in biopharma: Where promise meets pressure Tuesday, October 14, 2025 11:00 AM - 11:40 AM ET Virtual Behind the scenes at Isomorphic Labs We’re joined by Isomorphic Labs’ Chief Scientific Officer Miles Congreve and Chief AI Officer Max Jaderberg for an in-depth conversation. What’s next after Isomorphic’s $600 million raise this past winter — and are they finally ready to enter the clinic? Miles Congreve Chief Scientific Officer Isomorphic Labs Max Jaderberg Chief AI Officer Isomorphic Labs
Isomorphic Labs secures $2.1 Billion funding to scale its AI drug design engine - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Isomorphic Labs secures $2.1 Billion funding to scale its AI drug design engine May 12, 2026 | 5 min read Twitter LinkedIn Facebook Email Print Isomorphic Labs will use the funding to power its world-leading AI drug design engine, scale its business globally and progress its drug candidate pipeline. LONDO … and GV alongside new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund, significantly expanding Isomorphic Labs' global capital base. The new capital will be used for the continued development and deployment of Isomorphic Labs' AI drug design engine (IsoDDE), accelerating and expanding its pipeline of therapeutic programs towards the clinic. Additionally, the funding will support our existing hiring targets by integrating world-class AI, engineering, drug design … hroughs with a level of precision and speed previously thought impossible. "The application of AI in healthcare offers a profound opportunity. Isomorphic Labs has already made extraordinary progress in harnessing AI to accelerate drug discovery, and we are excited by this momentum and the early promise of the technology platform," said Ruth Porat, President and Chief Investment Officer Alphabet and Google. "This trajectory is encouraging, and this funding will be used to acce … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Isomorphic Labs - Wikipedia Jump to content Main menu Main menu move to sidebar hide Navigation Main page Contents Current events Random article About Wikipedia Contact us Contribute Help Learn to edit Community portal Recent changes Upload file Special pages Search Search Appearance Donate Create account Log in Personal tools Donate Create account Log in Contents move to sidebar hide (Top) 1 History 2 References 3 External links Toggle the table of contents Isomorphic Labs 9 languages Azərbaycanca Català Deutsch Français עברית Português Türkçe Українська 中文 Edit links Article Talk English Rea … the Creative Commons Attribution-ShareAlike 4.0 License ; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy . Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc. , a non-profit organization. Privacy policy About Wikipedia Disclaimers Contact Wikipedia Legal & safety contacts Code of Conduct Developers Statistics Cookie statement Mobile view Search Search Toggle the table of contents Isomorphic Labs 9 langu
Demis Hassabis - Wikipedia Jump to content Main menu Main menu move to sidebar hide Navigation Main page Contents Current events Random article About Wikipedia Contact us Contribute Help Learn to edit Community portal Recent changes Upload file Special pages Search Search Appearance Donate Create account Log in Personal tools Donate Create account Log in Contents move to sidebar hide (Top) 1 Early life and education Toggle Early life and education subsection 1.1 Bullfrog Productions 1.2 University of Cambridge 2 Career and research Toggle Career and research subsection 2.1 Lionhead 2.2 Elixir … e London ( PhD ) Known for DeepMind AlphaGo AlphaFold Awards Albert Lasker Award for Basic Medical Research (2023) Breakthrough Prize in Life Sciences (2023) Canada Gairdner International Award (2023) Nobel Prize in Chemistry (2024) Scientific career Fields Neuroscience Computer science Artificial intelligence Institutions University College London (2009–2012) [ 1 ] DeepMind (2010–present) Isomorphic Labs (2021–present) Thesis Neural Processes Underpinning Episod … 1; 12 ] In 2024, Hassabis and John M. Jumper were jointly awarded the Nobel Prize in Chemistry for their AI research contributions to protein structure prediction . [ 13 ] [ 14 ] [ 1 ] Hassabis is a Fellow of the Royal Society and has won awards for his research efforts, including the Breakthrough Prize , the Canada Gairdner International Award and the Lasker Award . He was appointed a CBE in 2017, and knighted in 2024 for his work on AI. [ 15 … iversity , [ 19 ] before earning a Henry Wellcome postdoctoral research fellowship to the Gatsby Computational Neuroscience Unit at UCL in 2009 working with Peter Dayan . [ 48 ] Working in the field of imagination, memory , and amnesia , he co-authored several influential papers published in Nature , Science , Neuron , and PNAS . [ 49 ] His very first academic work, published in PNAS , [ 50 ] was a landmark paper that showed systematically for … onsible for technical advances in machine learning, having produced a number of award-winning papers. In particular, the company has made significant advances in deep learning and reinforcement learning , and pioneered the field of deep reinforcement learning which combines these two methods. [ 75 ] Hassabis has predicted that artificial
Reimagining Drug Discovery Process with AI - Isomorphic Labs Our Team Our Tech Partnerships Careers Life At Iso Work With Us Job Openings News Our Team Our Tech Partnerships Careers Life at Iso Work with Us Job Openings News Solve all disease We’re entering a new era of drug discovery — one where frontier AI can unlock deeper scientific insights, faster breakthroughs, and life-changing medicines. At Isomorphic Labs, we’re building that future. Isomorphic Labs is here to advance human health by building on and beyond the Nobel-winning AlphaFold system. Our interdisciplinary team of drug discove … rld’s most devastating diseases. Our Tech “I believe there is no more important application for AI than helping to improve human health.” “I believe there is no more important application for AI than helping to improve human health.” SIR DEMIS HASSABIS FOUNDER AND CEO Latest from Iso Announcement Isomorphic Labs announces Series B investment round 18.02.25 Vision The Isomorphic Labs Drug Design Engine unlocks a new frontier beyond AlphaFold 18.02.25 Announcement Isomorphic La
Sir Demis Hassabis, PhD - Isomorphic Labs Our Team Our Tech Partnerships Careers Life At Iso Work With Us Job Openings News Our Team Our Tech Partnerships Careers Life at Iso Work with Us Job Openings News Back to Our Team Prev Next Prev Next Prev Next Prev Next Prev Next Prev Next Prev Next Prev Next Prev Next Prev Next Prev Next Prev Next Name Sir Demis Hassabis, PhD Title Founder and CEO Demis is our founder and CEO. He is also the founder and CEO of Google DeepMind and 2024 Nobel Laureate in Chemistry for his pioneering work on AlphaFold 2. A chess and programming prodigy, Demis is a compu … the 50-year grand challenge of protein folding. He designed and programmed the award-winning game Theme Park at the age of 17 and went on to graduate from Cambridge University and complete a PhD in cognitive neuroscience at University College London. Demis was awarded the 2024 Nobel Prize in Chemistry for protein structure prediction. His research has been featured by the journal Science in their Top 10 Breakthroughs of the Year four different times. Demis is a Fellow of the
Isomorphic Labs: Inside Iso - Included (Ep2) | Miles Congreve LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy
Isomorphic Labs announces first phase of management team - Isomorphic Labs Our Team Our Tech Partnerships Careers Life At Iso Work With Us Job Openings News Our Team Our Tech Partnerships Careers Life at Iso Work with Us Job Openings News Announcement Isomorphic Labs announces first phase of management team New additions include Chief Scientific Officer, Chief Technology Officer and Head of Machine Learning. New Alphabet “bet” is focused on the use of artificial intelligence to accelerate drug discovery May 1, 2022 min Read min Read min Read min Read min listen min watch Copy url Table of Cont … expensive and high-risk process that is poised to benefit from advances in the application of AI and computational methods. Studies peg the cost of bringing a molecule to market at more than $2.5 billion per drug and timelines approaching a decade; in fact, only about 12 percent of drugs entering clinical trials are ultimately approved by the U.S. Food and Drug Administration (FDA). “We’re thrilled to announce the formation of our extraordinary multidisciplinary leadership t … and patents. In 2015, he was co-recipient of the RSC Malcolm Campbell Memorial Prize for the seminal contributions to GPCR drug discovery made by Sosei Heptares. Dr. Congreve has a degree in biological chemistry from Leicester University and a PhD in synthetic chemistry from Cambridge University. He is also a fellow of the Royal Society of Chemistry. Sergei Yankeen, PhD Dr. Yakneen joins as Chief Technology Officer, bringing over 20 years of experience in engineering, machin
Miles Congreve, PhD - Isomorphic Labs Our Team Our Tech Partnerships Careers Life At Iso Work With Us Job Openings News Our Team Our Tech Partnerships Careers Life at Iso Work with Us Job Openings News Back to Our Team Prev Next Prev Next Prev Next Prev Next Prev Next Prev Next Prev Next Prev Next Prev Next Prev Next Prev Next Prev Next Name Miles Congreve, PhD Title Chief Scientific Officer Miles is our Chief Scientific Officer. He has helped design 29 clinically evaluated drugs and is co-inventor of Kisqali® (Ribociclib), a marketed treatment for breast cancers. As Chief Scientific Officer a … of Chemistry. In 2015, he was co-recipient of the RSC Malcolm Campbell Memorial Prize for the seminal contributions to GPCR drug discovery made by Sosei Heptares. Miles has a degree in biological chemistry from Leicester University and a PhD in synthetic chemistry from Cambridge University. “After more than 25 years working in drug discovery I can say that we get things wrong more times than we get them right. At Isomorphic Labs we are using everything we know in life science
Our Team - Isomorphic Labs Our Team Our Tech Partnerships Careers Life At Iso Work With Us Job Openings News Our Team Our Tech Partnerships Careers Life at Iso Work with Us Job Openings News Our Team Meet the people leading Iso We’re here to find solutions to the world’s most devastating diseases. Meet the Isos guiding us on the journey. Leadership Team Sir Demis Hassabis, PhD Founder and CEO Max Jaderberg, PhD President Miles Congreve, PhD Chief Scientific Officer Sarah Korman, PhD, JD Chief Business and Legal Officer Beverley Mallon Chief People Officer Sarah Skerratt, PhD Chief Research Off